The Trustees of North European Oil Royalty Trust (NYSE-NRT) announced today a quarterly distribution of $0.04 per unit ...

a growth of 16% on year-over-year and 4% Q-o-Q. This includes revenues from the acquired NRT business of Rs. 6,605 crores. Excluding NRT revenues, the underlying growth is at 7.5% on year-over ...

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

The increase was primarily driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, higher volumes and new product launches. Dr. Reddy’s launched four new ...

The Co-Chairman & MD, G V Prasad said that company's double-digit growth was aided by its newly acquired NRT business, new launches and improved operational efficiencies. "We remain committed to ...

The pharma major posted its highest ever quarterly results and Ebitda this quarter on the back of its recently acquired nicotine replacement therapy (NRT) portfolio, whose acquisition from Haleon ...

Growth in mainstay global generics revenue was largely driven by revenues from the nicotine replacement therapy (NRT) portfolio, outside of the U.S., acquired from British consumer healthcare firm ...

The pharma major maintained that underlying YoY growth excluding NRT is 7.5% and a decline of 3% QoQ. According to the company, the growth was largely driven by revenues from the recently acquired ...

Global generics revenue grew 17% YoY to $850 million, with 7% growth excluding NRT contributions and a 1% rise in North American sales. Get real-time earnings alerts before the market moves and ...